androgen ablation

(redirected from androgen suppression)
Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to androgen suppression: Androgen Deprivation Therapy, androgen ablation

androgen ablation

The therapeutic reduction of circulating androgens (testosterone and 5alpha-dihydrotestosterone) by either orchiectomy or by an luteinizing hormone-releasing hormone (LHRH) agonist. Androgen ablation is commonly used in metastatic prostate cancer and results in disease attenuation (12–18 months) in up to 80% of patients. Androgen ablation can be augmented by flutamide, an androgen receptor antagonist that blocks the effect of androgens produced by the adrenal gland.
References in periodicals archive ?
Intermittent androgen suppression was introduced in the 1980s as a means to reduce morbidity, but there remained controversy over the effectiveness of intermittent ADT (IADT) vs.
Medical versus surgical androgen suppression therapy for prostate cancer: A 10-year longitudinal cost study.
Hooton et al., "Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer," European Journal of Cancer, vol.
He has been using intermittent androgen suppression for more than 5 years in his patients and said the difference in quality of life is striking for these men.
The researchers found that androgen suppression therapy had a negative effect on vitality, which includes mood and energy.
When you think of cancer therapy, you tend to think of weight loss, but men who undergo combined androgen suppression therapy often gain 1520 pounds.
"The study team has a high degree of confidence that gabapentin, at a dose of 900 mg/day, moderately decreases hot flashes related to androgen suppression therapy," said Dr.
A phase 3 protocol of androgen suppression (AS) and 3DCRT/ IMRT vs.
A parallel study (RTOG 86-10) has shown that androgen suppression given before and during radiotherapy improved outcome in patients with Gleason 2-6 disease.
The Phase III Protocol of Androgen Suppression (AS) and 3DCTR/ IMRT Vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer (RTOG 0521) trial (4) randomized 562 men with high-risk localized prostate cancer treated with radiation and two years of androgen deprivation therapy (ADT), with and without the addition of adjuvant docetaxel (six cycles) and prednisone starting four weeks after radiation.

Full browser ?